Early research suggesting that a popular non-psychoactive compound derived from marijuana might help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.
If you are not happy with the results below please do another search
50 search results for:
Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.
Two cases of a subvariant of the Omicron variant were identified in Washington state. Two cases were also identified in Houston.
Johnson & Johnson on Jan. 25 forecast as much as $3.5 billion in sales of the company’s COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals. Additionally, J&J plans to take a more aggressive stance on deals for the company’s medical device unit.
Sierra Oncology shared positive topline results from the company’s study on the effectiveness of momelotinib to treat patients with myelofibrosis.
Ashfield Engage, part of UDG Healthcare, announced the acquisition of Medaxis, a patient engagement services partner for the life sciences industry that provides services to healthcare professionals and patients.
Evoke, a leading global health and wellness agency, announced the integration with San Francisco-based Evoke Giant to build a seamless North American client partner. The integration formally merges the two agencies while retaining the ability to service clients independently across the United States.
The U.S. health regulator revised on Jan. 24 the emergency use authorizations for COVID-19 antibody treatments from Regeneron and Eli Lilly to limit their use, as the drugs are unlikely to work against the Omicron coronavirus variant.
A New York judge struck down the state’s mask mandate on Jan. 24, one week before it was due to expire, ruling the governor overstepped her authority in imposing a rule that needed to have been passed by the state legislature.
The U.S. Food and Drug Administration granted Emergency Use Authorization for Mammoth Biosciences Inc.’s DETECTR BOOST SARS-CoV-2 Reagent Kit, a first of its kind high-throughput solution that combines the power of CRISPR with laboratory automation for SARS-CoV-2 testing.